Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption

References

• WangGSMedical uses of mylabris in ancient China and recent studiesJ Ethnopharmacol19892621471622689797
   PubMed Web of Science ®Google Scholar
• WangGSHydrolyze of norcantharidin and subtracting methyla alleviate stimulation of renal systemChin Pharm Bull19831871820
   Google Scholar
• YiSNWassJVincentPIlandHInhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitroLeuk Res199115108838861921448
   PubMed Web of Science ®Google Scholar
• EfferthTLiPCKonkimallaVSKainaBFrom traditional Chinese medicine to rational cancer therapyTrends Mol Med200713835336117644431
   PubMed Web of Science ®Google Scholar
• ShanHBCaiYCLiuYZengWNCytotoxicity of cantharidin analogues targeting protein phosphatase 2AAnticancer Drugs200617890591116940800
   PubMed Web of Science ®Google Scholar
• EfferthTRauhRKahlSMolecular modes of action of cantharidin in tumor cellsBiochem Pharmacol200569581181815710358
   PubMed Web of Science ®Google Scholar
• KokSHHongCYKuoMYComparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytesOral Oncol2003391192612457717
   PubMed Web of Science ®Google Scholar
• LiuXHBlazsekIComissoMEffects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cellsEur J Cancer199531A69539637646929
   PubMed Web of Science ®Google Scholar
• ChewaJLWolfowiczCBMaoHQLeongKWChuaKYChitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in miceVaccine20032121–222720272912798609
   PubMed Web of Science ®Google Scholar
• WuYYangWLWangCCHuJHFuSKChitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinateInt J Pharm20052951–223524515848008
   PubMed Web of Science ®Google Scholar
• LixinWHaibingHXingTRuiyingSDaweiCA less irritant norcantharidin lipid microspheres: Formulation and drug distributionInt J Pharm20063231–216116716828998
   PubMed Web of Science ®Google Scholar
• BalaIHariharanSKumarMNPLGA nanoparticles in drug delivery: the state of the artCri Rev Ther Drug Carrier Sys2004215387422
   PubMed Web of Science ®Google Scholar
• KatoYOnishiHMachidaYLactosaminated and intact N-succinylchitosans as drug carriers in liver metastasisInt J Pharm20012261–29310611532574
   PubMed Web of Science ®Google Scholar
• KatoYOnishiHMachidaYBiological characteristic of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in miceJ Control Release200170329530711182200
   PubMed Web of Science ®Google Scholar
• ZhangWLiuYChenXYTwo modelling data analytical methods applied to optimise the preparation of norcantharidin chitosan nanoparticlesJ Exp Nanosci201053271284
   Web of Science ®Google Scholar
• WangQZhangLHuWNorcantharidin-associated galactosylated chitosan nanoparticles for dual hepatocyte-targeted deliveryNanomedicine20106237138119699319
   PubMed Web of Science ®Google Scholar
• WagnerDSpahnLHHanafyAKoggelALangguthPIntestinal drug efflux: formulation and food effectsAdv Drug Deliv Rev200150Suppl 1S133111576693
   PubMed Web of Science ®Google Scholar
• KarlsMSRushBDWilkinsonKFVidmarTJBurtonPSRuwartMJDesolvation energy: a major determinant of absorption, but not clearance, of peptides in ratsPharm Res1991812147714811808609
   PubMed Web of Science ®Google Scholar
• ConradiRAHilgersARHoNFMaggioraLLThe influence of peptide structure on transport across Caco-2 cell. II. Peptide bond modification which results in improved permeabilityPharm Res1992934354391614980
   PubMed Web of Science ®Google Scholar
• StewartBHChanOHLuRHComparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humansPharm Res19951256936997479555
   PubMed Web of Science ®Google Scholar
• PalmKLuthmanKUngellALStrandlundGArturssonPCorrelation of drug absorption with molecular surface propertiesJ Pharm Sci199685132398926580
   PubMed Web of Science ®Google Scholar
• BarringtonRWilliamsonGBennettRNDavisBDBrodbeltJSKroonPAAbsorption, Conjugation and Efflux of the Flavonoids, Kaempferol and Galangin, Using the Intestinal CACO-2/TC7 Cell ModelJ Funct Foods200911748720046888
   PubMed Web of Science ®Google Scholar
• HillgrenKMKatoABorchardtRTIn vitro systems for studying intestinal drug absorptionMed Res Rev1995152831097537838
   PubMed Web of Science ®Google Scholar
• RubasWCromwellMEMShahrokhZFlux measurements across Caco-2 monolayers may predict transport in human large intestinal tissueJ Pharm Sci19968521651698683442
   PubMed Web of Science ®Google Scholar
• UngellALIn vitro absorption studies and their relevance to absorption from the GI tractDrug Dev Ind Pharm199723879892
   Web of Science ®Google Scholar
• ChungTWYangJAkaikeTPreparation of alginate/galactosylated chitosan scaffold for hepatocyte attachmentBiomaterials200223142827283412069321
   PubMed Web of Science ®Google Scholar
• ZhangXNTangLHYanXYZhangQAlbendazole polybutycyanocrylate nanoparticles-Preparation, pharmaceutical properties and tissue distribution in ratsLett Drug Des Discov20063275279
   Web of Science ®Google Scholar
• BanerjeeTMitraSSinghAKSharmaRKMaitraAPreparation, characterization and biodistribution of ultrafine chitosan nanoparticlesInt J Pharm20022431–29310512176298
   PubMed Web of Science ®Google Scholar
• LuEFranzblauSOnyukselHPopescuCPreparation of amino-glycoside- loaded chitosan nanoparticles using dextran sulphate as a counterionJ Microencapsul200926434635418726818
   PubMed Web of Science ®Google Scholar
• RubinsteinAPathakYVKleinsternJRechesABenitaSIn vitro release and intestinal absorption of physostigmine salicylate from submicron emulsionsJ Pharm Sci19918076436471941560
   PubMed Web of Science ®Google Scholar
• NornooAOZhengHLopesLBJohnson-RestrepoBKannanKReedROral microemulsions of paclitaxel: in situ and pharmacokinetic studiesEur J Pharm Biopharm200971231031718793723
   PubMed Web of Science ®Google Scholar
• LingWRuiLCHuaJXIn situ intestinal absorption behaviors of tanshinone IIA from its inclusion complex with hydroxypropyl- β-cyclodextrinBiol Pharm Bull2007301918192217917262
   PubMed Web of Science ®Google Scholar
• MichelCAprahamianMDefontaineLCouvreurPDamgéCThe effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic ratsJ Pharm Pharmacol1991431151676051
   PubMed Web of Science ®Google Scholar
• SasakiITanakaKFujitaTMurakamiMYamamotoAMuranishiSIntestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue 11: in situ and in vitro absorption characteristics of azetirelin from the rat intestineBiol Pharm Bull19951879769797581253
   PubMed Web of Science ®Google Scholar
• LiangHFYangTFHuangCTChenMCSungHWPreparation of nanoparticles composed of poly(γ-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cellsJ Control Release2005105321322515916830
   PubMed Web of Science ®Google Scholar
• WuJLiuLYenRPolycationic liposome-mediated extracellular superoxide dismutase gene delivery prevents acute liver injury in miceHepatology2003381240241
   Google Scholar
• YangHYZhangMGTargeting Drug Delivery SystemJournal of China-Japan Friendship Hospital2001155292294
   Google Scholar
• LiQZUsing Weibull function to seek dissolution parametersChinese Journal of Hospital Pharmacy19911113031
   Google Scholar
• MasaokaYTanakaYKataokaMSakumaSYamashitaSSite of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tractEur J Pharm Sci2006293–424025016876987
   PubMed Web of Science ®Google Scholar
• De BoerAGDrug Absorption Enhancement: Concepts, Possibilities, Limitations and TrendsChur, SwitzerlandHarwood Academic Publishers GmbH1994367389
   Google Scholar
• Cano-CebriánMJZornozaTGraneroLPolacheAIntestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug deliveryCurr Drug Deliv20052192216305404
   PubMedGoogle Scholar
• HaussDJFogalSEFicorilliJVLipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitorJ Pharm Sci19988721641699519148
   PubMed Web of Science ®Google Scholar
• HolmRMüllertzAPedersenGPKristensenHGComparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acidsPharm Res20011891299130411683243
   PubMed Web of Science ®Google Scholar
• O’DriscollCMLipid-based formulations for intestinal lymphatic deliveryEur J Pharm Sci200215540541512036717
   PubMed Web of Science ®Google Scholar
• KhooSMShacklefordDMPorterCJEdwardsGACharmanWNIntestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogsPharm Res20032091460146514567642
   PubMed Web of Science ®Google Scholar
• WanHJTangXYangDLAbsorption kinetics of ofloxacin in rats in situChinese Journal of Hospital Pharmacy2005257597599
   Google Scholar
• JiHYLiZZSunJRAbsorption mechanisms of protein and peptide in oral administrationShandong Pharm Ind2003223132
   Google Scholar
• CollnotEMBaldesCWempeMFMechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidityMol Pharm20074346547417367162
   PubMed Web of Science ®Google Scholar